SILENCE THERAP. SP.ADR/1 Net Asset Quality Index
SILENCE THERAP. SP.ADR/1 net asset quality index. SILENCE THERAP. SP.ADR/1 (XRP2) has a Net Asset Quality Index of 47.4% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €131.44 Million minus total liabilities of €69.14 Million yields net assets of €62.30 Million. A higher index indicates a stronger, lower-leverage balance sheet. See SILENCE THERAP. SP.ADR/1 shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of SILENCE THERAP. SP.ADR/1 (2021–2025)
Net asset quality index of SILENCE THERAP. SP.ADR/1 from 2021 to 2025. This chart shows how SILENCE THERAP. SP.ADR/1's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 47.4%, representing net assets of €62.30 Million against total assets of €131.44 Million EUR. Check XRP2 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
SILENCE THERAP. SP.ADR/1 Net Asset Quality Index by Year (2021–2025)
SILENCE THERAP. SP.ADR/1 net asset quality index by year from 2021 to 2025. The table below presents the year-by-year Net Asset Quality Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see SILENCE THERAP. SP.ADR/1 market cap and net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 47.4% | €62.30 Million | €131.44 Million | €69.14 Million | ▼ -18.7 pp |
| 2024 | 66.1% | €134.02 Million | €202.63 Million | €68.61 Million | ▲ +47.7 pp |
| 2023 | 18.4% | €21.99 Million | €119.45 Million | €97.45 Million | ▼ -2.1 pp |
| 2022 | 20.5% | €26.71 Million | €130.10 Million | €103.38 Million | ▲ +11.7 pp |
| 2021 | 8.9% | €11.51 Million | €129.83 Million | €118.32 Million | — |